WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience Advertisement
 QUICK SEARCH:   [advanced]


     
-


HOME
  |  
SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (109)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Palfi, S.
Right arrow Articles by Hantraye, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Palfi, S.
Right arrow Articles by Hantraye, P.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*3-NITROPROPIONIC ACID
*APOMORPHINE
Medline Plus Health Information
*Huntington's Disease

 Previous Article  |  Next Article 

Volume 16, Number 9, Issue of May 1, 1996 pp. 3019-3025
Copyright ©1996 Society for Neuroscience

Chronic 3-Nitropropionic Acid Treatment in Baboons Replicates the Cognitive and Motor Deficits of Huntington's Disease

Received Sept. 11, 1995; revised Jan. 23, 1996; accepted Feb. 9, 1996.

Stéphane Palfi1, 2, Robert J. Ferrante3, Emmanuel Brouillet1, M. Flint Beal4, Robert Dolan1, Marie Caroline Guyot1, Marc Peschanski2, and Philippe Hantraye1

1 URA CEA-CNRS 1285, Service Hospitalier Frédéric Joliot, DRIPP, CEA-DSV, 91401 ORSAY Cedex, France, 2 INSERM U 421, Faculté de Médecine, 94010 CRETEIL Cedex, France, 3 GRECC Unit, 182B, Bedford Veteran Administration Medical Center, Bedford, Massachusetts 01730, and Department of Neurology, Boston University Medical School, Boston, Massachusetts 02118, and 4 Neurochemistry Laboratory, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02114

We showed recently that chronic administration of the mitochondrial inhibitor 3-nitropropionic acid (3NP) in primates produces various dyskinetic movements and dystonic postures associated with selective striatal lesions displaying many similarities with the pathological features of Huntington's disease (HD). In the present study, we examined whether such a toxic treatment could also induce frontal-type deficits similar to those observed in HD patients. Cognitive performances of 3NP-treated and control baboons were compared using the object retrieval detour task (ORDT), a test designed to assess the functional integrity of the frontostriatal pathway in human and nonhuman primates. During the same time, the motor function of each animal was assessed under spontaneous ``no drug'' conditions, and time-sampled neurological observations were used after apomorphine administration. A significant impairment in the ORDT was observed in the 3NP animals after 3-6 weeks of treatment, occurring in the absence of spontaneous abnormal movements but in the presence of apomorphine-inducible dyskinesias. Prolonged 3NP treatment resulted in the progressive appearance of spontaneous abnormal movements. Histological evaluation of these animals showed selective bilateral caudate-putamen lesions with sparing of the cerebral cortex, notably the prefrontal cortex. The present study demonstrates that chronic 3NP treatment replicates in primates the basic pathophysiological triad of HD, including spontaneous abnormal movements, progressive striatal degeneration, and a frontostriatal syndrome of cognitive impairment.

Key words: Huntington's disease; basal ganglia; caudate nucleus; frontal cortex; baboon; 3-nitropropionic acid; object retrieval detour task; cognitive behavior; motor behavior; apomorphine testing




This article has been cited by other articles:


Home page
Cereb CortexHome page
M.S. Man, H.F. Clarke, and A.C. Roberts
The Role of the Orbitofrontal Cortex and Medial Striatum in the Regulation of Prepotent Responses to Food Rewards
Cereb Cortex, August 9, 2008; (2008) bhn137v1.
[Abstract] [Full Text] [PDF]


Home page
DevelopmentHome page
J. D. Mast, K. M. H. Tomalty, H. Vogel, and T. R. Clandinin
Reactive oxygen species act remotely to cause synapse loss in a Drosophila model of developmental mitochondrial encephalopathy
Development, August 1, 2008; 135(15): 2669 - 2679.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
H. Fukui and C. T. Moraes
Extended polyglutamine repeats trigger a feedback loop involving the mitochondrial complex III, the proteasome and huntingtin aggregates
Hum. Mol. Genet., April 1, 2007; 16(7): 783 - 797.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. J. Calkins, R. J. Jakel, D. A. Johnson, K. Chan, Y. W. Kan, and J. A. Johnson
Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription
PNAS, January 4, 2005; 102(1): 244 - 249.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Bizat, J.-M. Hermel, S. Humbert, C. Jacquard, C. Creminon, C. Escartin, F. Saudou, S. Krajewski, P. Hantraye, and E. Brouillet
In Vivo Calpain/Caspase Cross-talk during 3-Nitropropionic Acid-induced Striatal Degeneration: IMPLICATION OF A CALPAIN-MEDIATED CLEAVAGE OF ACTIVE CASPASE-3
J. Biol. Chem., October 31, 2003; 278(44): 43245 - 43253.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
D. Blum, D. Gall, M.-C. Galas, P. d'Alcantara, K. Bantubungi, and S. N. Schiffmann
The Adenosine A1 Receptor Agonist Adenosine Amine Congener Exerts a Neuroprotective Effect against the Development of Striatal Lesions and Motor Impairments in the 3-Nitropropionic Acid Model of Neurotoxicity
J. Neurosci., October 15, 2002; 22(20): 9122 - 9133.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
S. Sipione, D. Rigamonti, M. Valenza, C. Zuccato, L. Conti, J. Pritchard, C. Kooperberg, J. M. Olson, and E. Cattaneo
Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses
Hum. Mol. Genet., August 15, 2002; 11(17): 1953 - 1965.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
P. Calabresi, P. Gubellini, B. Picconi, D. Centonze, A. Pisani, P. Bonsi, P. Greengard, R. A. Hipskind, E. Borrelli, and G. Bernardi
Inhibition of Mitochondrial Complex II Induces a Long-Term Potentiation of NMDA-Mediated Synaptic Excitation in the Striatum Requiring Endogenous Dopamine
J. Neurosci., July 15, 2001; 21(14): 5110 - 5120.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
E. A. Bolan, K. N. Gracy, J. Chan, R. R. Trifiletti, and V. M. Pickel
Ultrastructural Localization of Nitrotyrosine within the Caudate-Putamen Nucleus and the Globus Pallidus of Normal Rat Brain
J. Neurosci., July 1, 2000; 20(13): 4798 - 4808.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
L. A. Lione, R. J. Carter, M. J. Hunt, G. P. Bates, A. J. Morton, and S. B. Dunnett
Selective Discrimination Learning Impairments in Mice Expressing the Human Huntington's Disease Mutation
J. Neurosci., December 1, 1999; 19(23): 10428 - 10437.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. T. Matthews, L. Yang, S. Browne, M. Baik, and M. F. Beal
Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects
PNAS, July 21, 1998; 95(15): 8892 - 8897.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
R. T. Matthews, L. Yang, B. G. Jenkins, R. J. Ferrante, B. R. Rosen, R. Kaddurah-Daouk, and M. F. Beal
Neuroprotective Effects of Creatine and Cyclocreatine in Animal Models of Huntington's Disease
J. Neurosci., January 1, 1998; 18(1): 156 - 163.
[Abstract] [Full Text] [PDF]



-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help

-
Copyright 2008 by Society for Neuroscience ONLINE ISSN: 1529-2401
-